[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014003704A2 - moduladores ror gama - Google Patents

moduladores ror gama

Info

Publication number
BR112014003704A2
BR112014003704A2 BR112014003704A BR112014003704A BR112014003704A2 BR 112014003704 A2 BR112014003704 A2 BR 112014003704A2 BR 112014003704 A BR112014003704 A BR 112014003704A BR 112014003704 A BR112014003704 A BR 112014003704A BR 112014003704 A2 BR112014003704 A2 BR 112014003704A2
Authority
BR
Brazil
Prior art keywords
diabetes
gamma modulators
ror gamma
treating
preventing
Prior art date
Application number
BR112014003704A
Other languages
English (en)
Inventor
Meissburger Bettina
Wolfrum Christian
Carreira Erick
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of BR112014003704A2 publication Critical patent/BR112014003704A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "moduladores ror gama". a presente invenção refere-se a compostos da fórmula i, ou um sal farmaceuticamente aceitável do mesmo, i para uso no tratamento ou prevenção, supressão ou melhora de uma doença mediado pelo receptor ror gama em um indivíduo em necessidade do mesmo, em particular diabetes e distúrbios relacionados a diabetes, especificamente diabetes tipo ii, métodos de sua produção, bem como métodos de tratamento ou prevenção de tais doenças.
BR112014003704A 2011-09-19 2012-09-18 moduladores ror gama BR112014003704A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11007610 2011-09-19
PCT/EP2012/068332 WO2013041519A1 (en) 2011-09-19 2012-09-18 Ror gamma modulators

Publications (1)

Publication Number Publication Date
BR112014003704A2 true BR112014003704A2 (pt) 2017-03-07

Family

ID=46852019

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003704A BR112014003704A2 (pt) 2011-09-19 2012-09-18 moduladores ror gama

Country Status (14)

Country Link
US (1) US9777036B2 (pt)
EP (1) EP2758060B1 (pt)
JP (2) JP2014526494A (pt)
KR (1) KR102020923B1 (pt)
CN (1) CN103957919B (pt)
AU (1) AU2012311599B2 (pt)
BR (1) BR112014003704A2 (pt)
DK (1) DK2758060T3 (pt)
ES (1) ES2659455T3 (pt)
NO (1) NO2758060T3 (pt)
PL (1) PL2758060T3 (pt)
PT (1) PT2758060T (pt)
RU (1) RU2658013C2 (pt)
WO (1) WO2013041519A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
KR20160055185A (ko) * 2013-09-11 2016-05-17 에프. 호프만-라 로슈 아게 RORc 조절제로서의 케토-이미다조피리딘 유도체
JP6463362B2 (ja) * 2013-12-19 2019-01-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ＲＯＲ−ガンマ阻害剤としてのテトラヒドロ−テトラゾロ［１，５−ａ］ピラジン
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
IL266261B (en) * 2016-10-27 2022-07-01 Escalier Biosciences Bv ror-gamma modulators
EP3662076A2 (en) 2017-08-03 2020-06-10 Vio Chemicals AG Method for preparing bile acid compound via enzymatic catalysis
CN109912676B (zh) * 2019-03-07 2021-08-27 上海科骊科生物技术有限公司 一种3β-熊去氧胆酸的制备方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126283A (ja) 1993-09-03 1995-05-16 Kunio Tsuji 胆汁アルコール
PT832094E (pt) * 1995-06-07 2004-06-30 Genaera Corp Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
JP2000026300A (ja) * 1998-07-02 2000-01-25 Pola Chem Ind Inc 血管内皮細胞保護医薬組成物
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
EP1219294A4 (en) 1999-09-20 2005-01-26 ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2406930C (en) * 2000-02-04 2011-02-15 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
ATE293101T1 (de) 2000-06-16 2005-04-15 Smithkline Beecham Plc Piperidine zur verwendung als orexin rezeptor antagonisten
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
PT1551860E (pt) 2002-06-19 2007-02-28 Karobio Ab Ligandos de receptores glucocorticóides para o tratamento de distúrbios metabólicos
US20090074895A1 (en) * 2005-05-02 2009-03-19 Vanadis Bioscience Ltd Composition and uses thereof
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
JPWO2009011420A1 (ja) * 2007-07-18 2010-09-24 田辺三菱製薬株式会社 ２型糖尿病の治療薬
CA2716922C (en) * 2008-02-26 2016-06-28 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders
CN102712672B (zh) 2009-08-25 2016-09-14 胆清医药有限公司 用于治疗胆疾病的多羟基化胆汁酸

Also Published As

Publication number Publication date
AU2012311599B2 (en) 2017-07-06
EP2758060B1 (en) 2017-11-29
KR20140079416A (ko) 2014-06-26
AU2012311599A1 (en) 2014-02-20
RU2014115796A (ru) 2015-10-27
US20140343023A1 (en) 2014-11-20
RU2658013C2 (ru) 2018-06-19
DK2758060T3 (en) 2018-03-05
KR102020923B1 (ko) 2019-09-11
ES2659455T3 (es) 2018-03-15
PT2758060T (pt) 2018-01-24
WO2013041519A1 (en) 2013-03-28
US9777036B2 (en) 2017-10-03
CN103957919B (zh) 2018-10-16
EP2758060A1 (en) 2014-07-30
JP2014526494A (ja) 2014-10-06
NO2758060T3 (pt) 2018-04-28
JP6439206B2 (ja) 2018-12-19
JP2018024651A (ja) 2018-02-15
WO2013041519A9 (en) 2013-06-27
PL2758060T3 (pl) 2018-04-30
NZ620485A (en) 2016-04-29
CN103957919A (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
BR112014003704A2 (pt) moduladores ror gama
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201170847A1 (ru) Тиазолопиридиновые соединения, регулирующие сиртуин
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112012012903A2 (pt) compostos de espiropiperidina
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
BR112014007357A2 (pt) métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
MX2014013499A (es) Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos.
PH12015500746A1 (en) Benzamides
BR112015007647A2 (pt) derivados de quetamina
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements